SOURCE: Elsevier Business Intelligence

Elsevier Business Intelligence

March 31, 2010 09:30 ET

Elsevier's 'IN3 Europe' Investor Conference in Paris, April 29-30, 2010, to Include "State of the Medical Device Industry" Plenary Session

Strategic Partnership and Investment Meeting Follows 'Medical Device Investor Day' at Same Venue on April 28th

PARIS--(Marketwire - March 31, 2010) -  Elsevier Business Intelligence, the Medtech industry's leading provider of strategic partnership and investment conferences, announced today that it will host 'IN3 Europe' on April 29-30, 2010, at The Marriott Rive Gauche, Paris. This annual conference will follow 'Medical Device Investor Day,' also being held at The Marriott Rive Gauche, on April 28th, 2010.

IN3 Europe is one of the largest annual strategic partnership and investment meetings in Europe for senior-level medical technology executives. An audience of several hundred -- including venture capital firms, corporate and other investors in the medtech sector -- is expected to attend IN3 Europe to hear from more than 40 emerging medical technology companies seeking funding and/or strategic partnerships.

IN3 Europe will include a 'must-attend' plenary session on the final day of the conference: "The State of the Medical Device Industry."

In addition, IN3 Europe will commence with a panel discussion: "Trends in European Dealmaking and Investing," which will be moderated by David Cassak, Managing Director, Elsevier Business Intelligence. Experts will include: Arthur Franken, Managing Partner, Gilde Healthcare Partners; Tim Haines, Partner, Abingworth; Olivier Litzka, Partner Life Sciences, Rothschilds; John Milad, Investment manager, NBGI; Antoine Papiernik, Managing Partner, Sofinnova Partners; Thom Rasche, Early Bird Ventures; and, Jay Watkins, Managing Director, De Novo Ventures.

Medical Device Investor Day will precede IN3 Europe and will appeal to medtech innovators interested in what medical technology investment leaders are thinking, doing, and planning. Venture and corporate investment professionals will speak about what interests them most among medical device technologies: therapeutic areas, products, and geographic markets. They will also discuss partnering opportunities, how to maximize visibility in front of large-company investors, and elaborate on their appetite for M&A activities in the near term. Participants from the podium will include Abbott Laboratories, Abingworth, Banexi Venture Partners, Bard, Becton Dickson, Boston Scientific, Boston Scientific Technologie Zentrum, Capricorn Venture Partners, Credit Agricole Private Equity, Delta Partners, De Novo Ventures, Earlybird Venture Capital, Edwards Lifesciences (Israel), Edwards Lifesciences, Forbion Capital Partners, Gilde Healthcare Partners, Hunza Ventures, Index Venture Management, Life Science Partners (LSP), Matignon Investissement & Gestion, NBGI Ventures, Rothschild Investment Partners, Seventure Partners, Sofimac Partners, Sofinnova Partners, Stryker Europe, Wellington Partners, and Ysios Capital, among others.

For more information about IN3 Europe and Medical Device Investor Day, please contact: Kristy Grimes at 1-480-985-9512 or Kayleen Kell at 1-888-290-2225 (USA only), or email IN3@Elsevier.com.

Additional IN3 events in 2010 -- June 9-11, IN3 East, Boston (www.IN3East.com), The Westin Copley Place; Oct. 27-29, IN3 Summit, San Francisco, Grand Hyatt. For more information, please contact: Kristy Grimes at 1-480-985-9512 or Kayleen Kell at 1-888-290-2225 (USA only), or email IN3@Elsevier.com.

About Elsevier Business Intelligence

Elsevier Business Intelligence, an Elsevier company, is a global information supplier providing business intelligence on regulatory, business and reimbursement issues that are vital to the healthcare industry. Through a range of products including publications, conferences, databases and reports, Elsevier Business Intelligence places biopharma and medical device professionals, and those who focus on these industries, at the forefront of knowledge, by providing the perfect combination of news and information together with penetrating insight and analysis. Elsevier Business Intelligence (http://www.elsevierbi.com) has offices in the U.S. in Bridgewater, N.J.; Norwalk, Conn.; Rockville, Md.; and Irvine, Calif.

About Elsevier

Elsevier is a world-leading publisher of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet (www.thelancet.com) and Cell (www.cell.com), and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier's online solutions include ScienceDirect (www.sciencedirect.com), Scopus (www.scopus.com), Reaxys (www.reaxys.com), MD Consult (www.mdconsult.com) and Nursing Consult (www.nursingconsult.com), which enhance the productivity of science and health professionals, and the SciVal suite (www.scival.com) and MEDai's Pinpoint Review (www.medai.com), which help research and health care institutions deliver better outcomes more cost-effectively.

A global business headquartered in Amsterdam, Elsevier (www.elsevier.com) employs 7,000 people worldwide. The company is part of Reed Elsevier Group PLC (www.reedelsevier.com), a world-leading publisher and information provider, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).

Contact Information